

**UCI 14-25**


Plasma Exosome Concentration  
in Cancer Patients Undergoing  
Treatment (Nelson)

**UCI 15-79**

Ph II Open-Label Randomized  
Radiosurgery w/ or w/o TT Fields  
for 1-10 Brain Metastases from  
NSCLC (Carrillo)

**UC 16-01**

Pathway Analyses for Individualized Network Therapeutics for Cancer (Ou)



# Lung Cancer Clinical Trials

## Single Mutation Driven Trials

### UCI 17-90

A two-part Phase I, open label, dose escalation study to evaluate the safety, tolerability and pharmacokinetics of pyrotinib in patients with HER2-positive solid tumors whose disease progressed on prior HER2 targeted therapy (Ou)

### UCI 17-50

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumor (Ou)

### UCI 16-96

A Phase 1 Study with Highly-selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and other Advanced Solid Tumors (Ou)

### UCI 07-40

Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, a C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer (Ou)

### \*\*UCI 17-101

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1) (Ou)

